Subscribe
zffoto-shutterstock-com-2
Zffoto / Shutterstock.com
10 February 2016Americas

Editas goes public amid CRISPR patent battle

A biotechnology company that licenses a patent related to the gene-editing technology CRISPR/Cas9 has raised more than $94 million in its initial share offering.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
USPTO ignites CRISPR/Cas9 patent battle
13 January 2016   Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Americas
USPTO ignites CRISPR/Cas9 patent battle
13 January 2016   Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More on this story

Americas
USPTO ignites CRISPR/Cas9 patent battle
13 January 2016   Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York